Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability

Gurkan-Alp A. S., Alp M., Karabay A. Z., Koç A., Buyukbingol E.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.20, no.14, pp.1728-1738, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 14
  • Publication Date: 2020
  • Doi Number: 10.2174/1871520620666200502001953
  • Journal Name: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.1728-1738
  • Keywords: Benzimidazole, breast cancer, cancer, docking, PARP-1 inhibitors, olaparib, INHIBITORS, DERIVATIVES, OLAPARIB
  • Ankara University Affiliated: Yes

Abstract

Background: Poly (ADP-ribosyl) polymerase-1 (PARP-1) inhibitors are compounds that are used to treat cancers, which are defective in DNA-repair and DNA Damage-Response (DDR) pathways.